Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

With Zydus Lifesciences Limited's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 1.938000
forwardPE 22.764942
debtToEquity 34.305000
earningsGrowth 0.381000
revenueGrowth 0.169000
grossMargins 0.715810
operatingMargins 0.212270
trailingEps 48.930000
forwardEps 0.000000

With a current ratio 1.938, Zydus Lifesciences Limited demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
ZYDUSLIFE's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
Zydus Lifesciences Limited's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as Zydus Lifesciences Limited's increasing profits and sales signal further growth in the near future.
Zydus Lifesciences Limited's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Over time, ZYDUSLIFE's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


1 transactions to buy ZYDUSLIFE took place, with market price at 951.4000244140625 per share.There were no buy transactions during the given timeframe.More sells than buys at Zydus Lifesciences Limited's current price levels suggest potential weakness. If this trend continues, the stock may experience further price declines as selling pressure increases.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Recent analysis shows a strong buy bias for ZYDUSLIFE, encouraging investors to view it as a solid investment option. The positive sentiment surrounding ZYDUSLIFE suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.